$262 Million is the total value of CHI Advisors LLC's 28 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 27.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RXDX | Buy | PROMETHEUS BIOSCIENCES INC | $47,200,000 | -21.1% | 1,671,976 | +5.5% | 18.03% | -29.2% |
| CGEM | Buy | CULLINAN ONCOLOGY INC | $39,070,000 | +35.5% | 3,047,609 | +10.7% | 14.92% | +21.7% |
| RPTX | Buy | REPARE THERAPEUTICS INC | $37,028,000 | +0.7% | 2,646,781 | +2.5% | 14.14% | -9.5% |
| PLRX | Buy | PLIANT THERAPEUTICS INC | $24,886,000 | +33.6% | 3,106,807 | +16.9% | 9.50% | +20.0% |
| VECT | Buy | VECTIVBIO HLDG AG | $20,424,000 | +40.6% | 3,782,199 | +22.6% | 7.80% | +26.3% |
| KZR | Buy | KEZAR LIFE SCIENCES INC | $15,223,000 | +191.1% | 1,840,793 | +485.1% | 5.81% | +161.4% |
| 2SEVENTY BIO INC | $10,820,000 | -22.6% | 819,672 | 0.0% | 4.13% | -30.5% | ||
| INZY | Buy | INOZYME PHARMA INC | $9,701,000 | +165.9% | 2,033,802 | +128.0% | 3.70% | +138.7% |
| CMPX | COMPASS THERAPEUTICS INC | $7,499,000 | +93.4% | 2,829,712 | 0.0% | 2.86% | +73.7% | |
| IKNA | Buy | IKENA ONCOLOGY INC | $4,833,000 | -2.8% | 1,090,937 | +33.9% | 1.85% | -12.6% |
| DTIL | Buy | PRECISION BIOSCIENCES INC | $4,806,000 | +157.3% | 3,003,751 | +395.2% | 1.84% | +131.2% |
| NKTX | New | NKARTA INC | $4,411,000 | – | 358,013 | +100.0% | 1.68% | – |
| FRLN | FREELINE THERAPEUTICS HLDGSsponsored ads | $4,230,000 | -22.3% | 4,862,319 | 0.0% | 1.62% | -30.2% | |
| OMEGA THERAPEUTICS INC | $4,012,000 | -39.1% | 1,055,882 | 0.0% | 1.53% | -45.3% | ||
| AKUS | AKOUOS INC | $3,921,000 | -1.3% | 836,120 | 0.0% | 1.50% | -11.3% | |
| GTHX | Buy | G1 THERAPEUTICS INC | $3,790,000 | +2.0% | 767,235 | +57.0% | 1.45% | -8.4% |
| ORTX | ORCHARD THERAPEUTICS PLCads | $3,101,000 | -17.9% | 5,307,751 | 0.0% | 1.18% | -26.3% | |
| ONCR | Sell | ONCORUS INC | $2,983,000 | -30.7% | 2,367,436 | -2.1% | 1.14% | -37.8% |
| LRMR | LARIMAR THERAPEUTICS INC | $2,970,000 | -51.6% | 1,515,148 | 0.0% | 1.13% | -56.5% | |
| KROS | Buy | KEROS THERAPEUTICS INC | $2,858,000 | -15.5% | 103,429 | +66.2% | 1.09% | -24.1% |
| CRVS | Buy | CORVUS PHARMACEUTICALS INC | $2,192,000 | -21.5% | 2,214,184 | +30.0% | 0.84% | -29.5% |
| New | ENTRADA THERAPEUTICS INC | $1,991,000 | – | 163,496 | +100.0% | 0.76% | – | |
| OVID | Buy | OVID THERAPEUTICS INC | $1,859,000 | -30.6% | 864,822 | +1.4% | 0.71% | -37.7% |
| EIGR | New | EIGER BIOPHARMACEUTICALS INC | $1,197,000 | – | 190,000 | +100.0% | 0.46% | – |
| PHAS | New | PHASEBIO PHARMACEUTICALS INC | $450,000 | – | 750,000 | +100.0% | 0.17% | – |
| XBI | Sell | SPDR SER TRput | $372,000 | +80.6% | 157,000 | -29.4% | 0.14% | +61.4% |
| EIGR | New | EIGER BIOPHARMACEUTICALS INCcall | $4,000 | – | 25,100 | +100.0% | 0.00% | – |
| KZR | New | KEZAR LIFE SCIENCES INCcall | $5,000 | – | 100,000 | +100.0% | 0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PRECISION BIOSCIENCES INC | 17 | Q3 2023 | 13.4% |
| OVID THERAPEUTICS INC | 17 | Q3 2023 | 5.8% |
| CORVUS PHARMACEUTICALS INC | 16 | Q2 2023 | 1.8% |
| KEZAR LIFE SCIENCES INC | 15 | Q1 2023 | 5.8% |
| PLIANT THERAPEUTICS INC | 14 | Q3 2023 | 29.2% |
| REPARE THERAPEUTICS INC | 14 | Q3 2023 | 30.3% |
| ORCHARD THERAPEUTICS PLC | 14 | Q4 2022 | 52.6% |
| LARIMAR THERAPEUTICS INC | 14 | Q3 2023 | 9.1% |
| KEROS THERAPEUTICS INC | 14 | Q3 2023 | 8.6% |
| INOZYME PHARMA INC | 13 | Q3 2023 | 9.4% |
View CHI Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Corvus Pharmaceuticals, Inc. | February 13, 2023 | 2,384,402 | 5.1% |
| Cullinan Oncology, Inc. | February 13, 2023 | 3,317,544 | 7.2% |
| Freeline Therapeutics Holdings plc | February 13, 2023 | 4,814,419 | 7.4% |
| Inozyme Pharma, Inc. | February 13, 2023 | 2,204,876 | 5.5% |
| Larimar Therapeutics, Inc. | February 13, 2023 | 3,473,366 | 8.0% |
| Oncorus, Inc. | February 13, 2023 | 2,367,436 | 9.1% |
| Orchard Therapeutics plc | February 13, 2023 | 7,987,396 | 6.3% |
| PLIANT THERAPEUTICS, INC. | February 13, 2023 | 3,199,892 | 6.6% |
| Repare Therapeutics Inc. | February 13, 2023 | 2,800,126 | 6.7% |
| VectivBio Holding AG | February 13, 2023 | 5,492,893 | 8.8% |
View CHI Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-13 |
| 13F-HR/A | 2023-08-22 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-11 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
View CHI Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.